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Abstract
Background: This paper includes a short description of the important clinical aspects of Bipolar Disorder with emphasis on 
issues that are important for the therapeutic considerations, including mixed and psychotic features, predominant polarity, 
and rapid cycling as well as comorbidity.
Methods: The workgroup performed a review and critical analysis of the literature concerning grading methods and methods 
for the development of guidelines.
Results: The workgroup arrived at a consensus to base the development of the guideline on randomized controlled trials and 
related meta-analyses alone in order to follow a strict evidence-based approach. A critical analysis of the existing methods 
for the grading of treatment options was followed by the development of a new grading method to arrive at efficacy and 
recommendation levels after the analysis of 32 distinct scenarios of available data for a given treatment option.
Conclusion: The current paper reports details on the design, method, and process for the development of CINP guidelines for the 
treatment of Bipolar Disorder. The rationale and the method with which all data and opinions are combined in order to produce 
an evidence-based operationalized but also user-friendly guideline and a specific algorithm are described in detail in this paper.
Keywords: Bipolar Disorder; anticonvulsants; antidepressants; antipsychotics; evidence-based guidelines; lithium; mania; 
bipolar depression; mood stabilizers; treatment
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Introduction
General Background, Disclosure, and Aim
Treatment guidelines are becoming an ever more important part 
of medical reality, especially since the translation of research 
findings to everyday clinical practice is becoming increasingly 
difficult with the accumulation of complex and often con-
flicting research findings that are thereafter also included in 
metaanalysis. Guidelines aim to assist clinicians but also poli-
cymakers to arrive at decisions concerning the treatment and 
care of patients. They set the standard of care and training for 
health professionals and they also identify priority areas for fur-
ther research, since they are based primarily on the available 
evidence, but also in areas where evidence is not available, on 
expert opinion (Fountoulakis, 2015i).
In the field of Bipolar Disorder (BD), accumulated knowledge 
is often complex, confusing, and in many instances contrasts 
with the beliefs and pracices that appear to have been set in 
stone in psychiatric culture and training for the last few decades.
To fulfil this need for expert translation of research findings 
into clinical practice for the benefit of patients, the International 
College of Neuropsychopharmacology (CINP) launched an effort 
to critically appraise the literature and provide guidance to clini-
cians in the form of a precise treatment algorithm. It is hoped 
that this algorithm for the treatment of BD will help the clini-
cian to follow the state-of-the-art evidence, thus enabling their 
clinical practice to be based on an informed decision-making 
process. This guideline has been commissioned by the CINP, 
and the workgroup consisted of experts with extensive research 
and clinical experience in the field of BDs. There was no funding 
from any source for the development of the guidelines and the 
activities of the workgroup.
All the members of the workgroup were psychiatrists who 
are in active clinical practice and were selected according to 
their expertise and with the aim to cover a multitude of some 
different cultures. All of them were involved in research and 
other academic activities, and therefore it is is possible that 
through such activities some contributors have received income 
related to medicines discussed in this guideline. All conflicts of 
interest are mentioned at the end of this paper, which is the 
introductory paper to the CINP BD guidelines. It should also be 
noted that some drugs recommended in the guideline may not 
be available in all countries, and labeling and dosing might vary.
The aim of the current endeavor was to develop a guideline 
and precise algorithm for treatment of BD in adults for use in 
primary and secondary care. Children, adolescents, and the 
elderly are not the focus of this guidance. The guideline and 
algorithm have been developed after a complete review of the 
literature and with the use of stringent criteria. Both the guide-
line and the precise algorithm try to balance research vs clinical 
wisdom but give primacy to the available evidence.
To comply with the journal’s word limit for manuscripts and 
for easy readability, the CINP guidelines have been organized 
and presented as a series of 4 distinct papers. This paper is the 
first of this series and will cover the general background of the 
guideline and algorithm, that is, the historical perspective and 
general clinical and treatment issues followed for the devel-
opment of the guideline and the algorithm. The second paper 
summarizes, classifies, and grades the treatment data on BD 
while the third paper includes the guideline and the treatment 
algorithm themselves. The fourth and final paper addresses the 
unmet needs and areas that should be the focus of attention 
and specific research in the future.
Historical Perspective
Depression and bipolarity were mentioned in Eber’s papyrus 
in ancient Egypt around 3000 BC (Okasha and Okasha, 2000) 
and in the Hippocratic texts. Plato (424–348 BC) and Aristotles 
(384–322 BC) further elaborated on the concept and Aristotle was 
the first to describe accurately the affections of desire, anger, 
fear, courage, envy, joy, hatred, and pity. Later, Galen (131–201 
AD), Themison of Laodicea (1st century BC) and Aretaeus of 
Cappadocia (2nd century AD) as well as Arab scholars and espe-
cially Avicenna (980–1037) further elaborated on the concept of 
mood disorders (Fountoulakis, 2015b).
Jean-Philippe Esquirol (1772–1840) was the first to clearly 
point out that melancholia was a disorder of the mood with 
“partial insanity” (monomania) and used the word “lypemania.” 
Finally, Jean-Pierre Falret (1794–1870) and Jules Gabriel Francois 
Baillarger (1809–1890) established the connection between 
depression and mania and gave it the name of “folie circulaire” 
or “folie à double forme,” but it was Emil Kraepelin (1856–1926) 
who established manic-depressive illness as a distinct nosologi-
cal entity and separated it from schizophrenia on the basis of 
heredity, longitudinal follow-up, and a supposed favorable out-
come (Kraepelin, 1921). His pupil Wilhelm Weygandt (1870–1939) 
published the first textbook on mixed clinical states (Weygandt, 
1899). Following a similar line of thinking, and in spite of some 
major objections to the Kraepelinian approach, Karl Jaspers 
(1883–1969) described aspects of mixed depressive states that 
he named “querulant mania,” “nagging depression,” or “wailing 
melancholia” (Jaspers, 1913), while Eugene Bleuler coined the 
term “affective illness” and by this he broadened the concept of 
manic-depression.
In 1957 Karl Leonhard (1902–1988) proposed that the term 
“bipolar disorder” should replace manic-depression, and he also 
made a distinction between monopolar (unipolar depression) 
and bipolar illness (Leonhard, 1957a, 1957b; Leonhard, 1979).
In 1870, Silas Weir Mitchell (1829–1914) was the first to rec-
ommend lithium as an anticonvulsant, hypnotic, and as medi-
cation for “general nervousness” (Mitchell, 1870, 1877). In 1871, 
William Alexander Hammond (1828–1900) was probably the first 
to prescribe a modern and effective psychotropic agent, and 
this was lithium (Mitchell and Hadzi-Pavlovic, 2000). Carl Lange 
(1834–1900) and Frederik Lange (1842–1907) had used lithium 
in the treatment of depression since 1886 (Lenox and Watson, 
1994). However, in spite of encouraging results, by the turn of the 
20th century, the “brain gout” theory of mood disorders disap-
peared as a medical entity and the use of lithium in psychiatry 
was abandoned.
In 1949 John Cade (1912–1980) reported positive results from 
the treatment of 10 acutely manic patients (Cade, 1949, 2000); 
however, 2  years later he reported the first death caused by 
lithium toxicity in a patient whose bipolar illness otherwise 
responded extremely well to treatment. Later, Mogens Schou 
(1918–2005) undertook a randomized controlled trial of lithium 
in mania (Schou et al., 1954; Bech, 2006), and eventually the the 
efficacy of lithium during the maintenance phase was estab-
lished (Gershon and Yuwiler, 1960; Baastrup, 1964; Baastrup and 
Schou, 1967; Angst et al., 1969, 1970; Baastrup et al., 1970; Schou 
et al., 1970; Johnstone et al., 1988; Schioldann, 1999; Mitchell and 
Hadzi-Pavlovic, 2000; Bech, 2006; Schioldann, 2006; Schioldann, 
2011).
Valproate was introduced in 1966 as an anticonvulsant 
(Lambert et  al., 1966) and later carbamazepine (Okuma et  al., 
1979) followed. Neuroleptics were introduced by Jean Delay 
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(1907–1987) and Pierre Deniker (1917–1999) in 1955, and prob-
ably many of their patients were suffering from acute mania 
or schizoaffective disorder (Delay and Deniker, 1955). In 1958 
Roland Kuhn (1912–2005) reported on the efficacy of the first 
antidepressant, imipramine (Kuhn, 1958).
There were several reports in the 1970s suggesting that in 
bipolar depression the use of antidepressants might induce 
mania, mixed episodes, and rapid cycling (Wehr and Goodwin, 
1987; Wehr et al., 1988). In 1994 the first detailed operational treat-
ment guidelines were published by the American Psychiatric 
Association and after 2000, systematic industry-sponsored 
studies of second generation antipsychotics and haloperidol 
were performed. Also, during this period the first meta-analytic 
studies emerged, and the evidence-based medicine principles 
gained ground in treatment recommendations.
Clinical Description
While the basic conception of BD suggested that it is charac-
terized by the alternation of manic and depressive episodes 
with a return to the premorbid level of functioning between the 
episodes and to favorable outcome compared with schizophre-
nia (Kraepelin, 1921), today we know that this is not always the 
case (Tohen et  al., 1990; Grande et  al., 2016). Not only BD is a 
much more complex disorder than this, but also the outcome 
varies. The most prominent clinical facets are shown in Table 1 
(Fountoulakis, 2015a, 2015c, 2015d, 2015e, 2015j, 2015n).
The fact that often the correct diagnosis is made only after 
8 to 10 years have passed because the first episode is psychotic-
like or depressive and the correct diagnosis can be made only 
after a manic or a mixed episode emerges (Angst, 2007) is espe-
cially problematic. It has been estimated that more than one-
half of hospitalized patients originally manifesting a depressive 
episode will turn out to be bipolars in the next 20 years (Angst 
et al., 2005a). It is of utmost importance for both clinicians and 
researchers to create a biographical chart with the patient’s 
course over time and including any important event in the 
developmental history of the patient and emphasizing the main 
events and hallmarks of his/her life and his/her full psychiatric 
and medical history. Such a chart clarifies both the diagnosis 
and the course of the disease and also the response to therapeu-
tic interventions, since any delay in the proper diagnosis also 
delays proper treatment (Altamura et al., 2010; Drancourt et al., 
2013).
In terms of individual symptoms, fatigue and psychomotor 
retardation dominate the clinical picture in 75% of patients dur-
ing acute bipolar depression. Irritability is present in almost 75% 
of patients (Winokur et al., 1969), delusions are present in 12 to 
66% (Winokur et al., 1969; Carlson and Strober, 1978; Rosenthal 
et al., 1980; Black and Nasrallah, 1989), and hallucinations in 8 to 
50% (Winokur et al., 1969; Carlson and Strober, 1978; Rosenthal 
et  al., 1980; Black and Nasrallah, 1989; Baethge et  al., 2005). 
Psychotic features seem to constitute a stable trait that tends 
to repeat itself across episodes (Helms and Smith, 1983; Nelson 
et al., 1984; Aronson et al., 1988a, 1988b). Depending of the study 
sample composition, changes in appetite for food are seen in 
almost all patients (Winokur et al., 1969), with one-fourth mani-
festing overeating and one-fourth losing significant weight 
(Casper et al., 1985). Almost all bipolar depressed patients expe-
rience some kind of sleep problem (Winokur et al., 1969; Casper 
et al., 1985). Α subgroup of bipolar depressed patients (up to 25%) 
often exhibit excessive sleep and have difficulty getting up in 
the morning (Winokur et al., 1969). Decreased sexual desire is 
seen in more than 75% of patients (Winokur et al., 1969; Casper 
et al., 1985) and concerns both sexes. Approximately two-thirds 
of bipolar depressed patients present with multiple physical 
pains and complaints (e.g., headache, epigastric pain, precordial 
distress, etc.) in the absence of any physical illness, especially in 
primary care (Winokur et al., 1969).
Euphoria is observed in 30 ot 97% of acutely manic patients 
(Clayton and Pitts, 1965; Winokur et al., 1969; Beigel and Murphy, 
1971; Carlson and Goodwin, 1973; Taylor and Abrams, 1973; 
Winokur and Tsuang, 1975; Abrams and Taylor, 1976; Leff et al., 
1976; Loudon et al., 1977; Taylor and Abrams, 1977; Cassidy et al., 
1998a), while unrestrained and expansive mood is seen in 44 to 
66% (Taylor and Abrams, 1973, 1977; Loudon et al., 1977). Patients 
are dissatisfied and intolerant and the vast majority manifest 
mood lability and instability (42 to 95%) (Winokur et al., 1969; 
Carlson and Goodwin, 1973; Abrams and Taylor, 1976; Loudon 
et  al., 1977; Taylor and Abrams, 1977; Cassidy et  al., 1998a). 
Irritability is also very frequent (51–100%) (Winokur et al., 1969; 
Carlson and Goodwin, 1973; Taylor and Abrams, 1973, 1977; 
Winokur and Tsuang, 1975; Abrams and Taylor, 1976; Loudon 
et  al., 1977; Cassidy et  al., 1998a; Serretti and Olgiati, 2005). 
However, even significant depressive symptoms are experienced 
by as many as 29 to 100% of acutely manic patients (Winokur 
et al., 1969; Beigel and Murphy, 1971; Kotin and Goodwin, 1972; 
Carlson and Goodwin, 1973; Murphy and Beigel, 1974; Loudon 
et al., 1977; Prien et al., 1988; Cassidy et al., 1998a; Bauer et al., 
2005).
Accelerated psychomotor activity is observed in the vast 
majority of patients (56–100%) (Winokur et  al., 1969; Carlson 
and Goodwin, 1973; Taylor and Abrams, 1973; Abrams and 
Taylor, 1976; Leff et  al., 1976; Loudon et  al., 1977; Carlson and 
Strober, 1978; Cassidy et al., 1998a, 1988b; Cassidy et al., 1998a; 
Serretti and Olgiati, 2005) and pressured speech in almost all 
patients (Clayton and Pitts, 1965; Winokur et al., 1969; Carlson 
and Goodwin, 1973; Taylor and Abrams, 1973; Abrams and Taylor, 
1976; Leff et al., 1976; Loudon et al., 1977; Carlson and Strober, 
1978; Cassidy et  al., 1998b; Serretti and Olgiati, 2005); hyper-
sexuality is present in 25 to 80% of patients with 23 to 33% of 
them having significant sexual exposure (Allison and Wilson, 
1960; Clayton and Pitts, 1965; Winokur et al., 1969; Carlson and 
Goodwin, 1973; Taylor and Abrams, 1973, 1977; Abrams and Taylor, 
1976; Leff et al., 1976; Loudon et al., 1977; Carlson and Strober, 
1978). Decreased need for sleep (hyposomnia) is present in 63 to 
100% of patients (Clayton and Pitts, 1965; Winokur et al., 1969; 
Leff et al., 1976; Loudon et al., 1977; Carlson and Strober, 1978; 
Table  1. List of the Multiple Clinical Aspects of Manic-Depressive 
Illness
 1. Manic episodes
 2. Depressive episodes
 3. Mixed episodes
 4. Subthreshold manic symptoms
 5. Subthreshold depressive symptoms
 6. ‘Mixed’ states and ‘roughening’
 7. Mood lability/cyclothymia/’personality-like’ behavior
 8. Predominant polarity
 9. Frequency of episodes/rapid cycling
10. Psychotic features
11. Neurocognitive disorder
12. Functional deficit and disability
13. Drug/alcohol abuse
14. Comorbid anxiety and other mental disorders
15. Self-destructive behavior and suicidality
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Cassidy et  al., 1998b; Serretti and Olgiati, 2005) and psychotic 
features in 33 to 96% of patients (Winokur et al., 1969; Carlson 
and Strober, 1978; Rosenthal et  al., 1980; Black and Nasrallah, 
1989).
Overall, psychotic features are so common that acute mania 
should be considered primarily a psychotic state (Koukopoulos, 
2006). Delusions are present in 24 to 96% of manic patients, and 
it is interesting that persecutory ideas are equally frequent with 
delusions of grandiose (Bowman and Raymond, 1932; Rennie, 
1942; Astrup et al., 1959; Clayton and Pitts, 1965; Winokur et al., 
1969; Beigel and Murphy, 1971; Carlson and Goodwin, 1973; 
Taylor and Abrams, 1973, 1977; Murphy and Beigel, 1974; Abrams 
and Taylor, 1976; Leff et al., 1976; Loudon et al., 1977; Carlson and 
Strober, 1978; Rosenthal et  al., 1980; Winokur, 1984; Black and 
Nasrallah, 1989; Serretti et al., 2002; Keck et al., 2003; Goodwin 
and Jamison, 2007). Hallucinations are less frequent and present 
in 13 to 66% of cases; they can either be congruent or noncon-
gruent, with auditory, visual, and olfactory ones being almost 
equally frequent (Lange, 1922; Bowman and Raymond, 1932; 
Astrup et  al., 1959; Winokur et  al., 1969; Taylor and Abrams, 
1973, 1977; Abrams and Taylor, 1976; Carlson and Strober, 1978; 
Rosenthal et al., 1980; Winokur, 1984; Black and Nasrallah, 1989; 
Serretti et al., 2002; Keck et al., 2003; Goodwin and Jamison, 2007).
Psychotic symptoms in BD are predictive of a more detrimen-
tal course, including a higher rate of rehospitalizations (Caetano 
et al., 2006; Ozyildirim et al., 2010).
Almost one-third of acutely manic patients are “confused” 
and 46 to 75% are violent (Carlson and Goodwin, 1973; Taylor 
and Abrams, 1973, 1977; Abrams and Taylor, 1976; Cassidy et al., 
1998b). The term confused refers to manic disorganization and 
not to organic drop in the level of consciousness. As many as 
14 to 56% of patients manifest severe regression, catatonia, 
posturing, and negativism, often making differential diagnosis 
from schizophrenia difficult (Lange, 1922; Carlson and Goodwin, 
1973; Taylor and Abrams, 1973, 1977; Carlson and Strober, 1978; 
Abrams and Taylor, 1981; Braunig et al., 1998; Kruger et al., 2003), 
and 10 to 20% have fecal incontinence (Taylor and Abrams, 1973, 
1977; Abrams and Taylor, 1976). A summary of the frequencies of 
appearance of various symptoms during the two different acute 
phases of the illness is shown in Table 2.
Formally, those episodes with manic symptoms but less pro-
nounced in terms of severity and with a shorter duration are 
labeled hypomanic. Hypomania is much more common than 
mania (Angst, 1998), but its recognition is mostly achieved 
mainly by interviewing significant others and not the patient. 
Hypomanic episodes cause mild or no impairment at all, and 
on the contrary, in some cases, they may even contribute to suc-
cess in business, leadership roles, and the arts. Psychotic symp-
toms are less frequent (around 20%) in comparison to full-blown 
manic episodes, but they do occur (Mazzarini et al., 2010).
Mixed episodes are defined as the coexistence of both 
depressive and manic symptoms; however, the term was aban-
doned with DSM-5, which includes mixed features as a specifier 
only. The DSM-5 demands the presence of a full-blown episode 
of either pole together with at least 3 symptoms of the opposite 
pole being present in order to allow the label of “mixed features” 
specifier.
It is reported that in 69.6% of cases the course resembles that 
of a recurrent episodic illness, while in 25% of cases there is a 
chronic course without clear remissions between episodes. In 
only 5.4% is there a single episode of mania. Suicidal ideation 
is present in 78.6% of patients at some time in their life. Only 
around 5% of BD patients have chronic mania (Akiskal, 2000).
Karl Leonhard was the first to report the presence of a pre-
dominant polarity with 17.9% of patients having a manic- and 
25.6% having a depressive-predominant polarity (Leonhard, 
1963). The concept was further formulated by Jules Angst (1978) 
and Carlo Perris (Perris and d’Elia, 1966a, 1966b) and has recently 
been utilized for long-term prognosis and to assist clinicians in 
long-term therapeutic design (Quitkin et  al., 1986; Judd et  al., 
2003; Colom et  al., 2006). The most reliable definition of pre-
dominant polarity demands that at least two-thirds of episodes 
belong to one of the poles (Colom et al., 2006; Rosa et al., 2008; 
Garcia-Lopez et  al., 2009; Mazzarini et  al., 2009; Tohen et  al., 
2009; Vieta et al., 2009; Nivoli et al., 2011; Baldessarini et al., 2012; 
Pacchiarotti et al., 2013a; Carvalho et al., 2014a, 2014b).
Somewhere between 15% and 50% of BD patients are 
reported to manifest some type of seasonal variation of symp-
tomatology (Hunt et al., 1992; Faedda et al., 1993; Goikolea et al., 
2007; Shand et al., 2011). Two opposing seasonal variations have 
been described: fall-winter depression with or without spring-
summer mania or hypomania; and spring-summer depres-
sion with or without fall-winter mania or hypomania (Faedda 
et al., 1993). Most studies support the first subtype (Walter, 1977; 
Parker and Walter, 1982; Mulder et al., 1990; Peck, 1990; Partonen 
and Lonnqvist, 1996; Clarke et al., 1999; Lee et al., 2007; Murray 
et al., 2011).
Τhe concept of rapid cycling appeared for the first time in the 
70s in a landmark paper by Dunner and Fieve (1974). In general 
the classic rapid-cycling includes cycles with duration of weeks 
to months. Ultra-rapid cycling is reported when mood cycling 
has frequency of weeks to days, and ultradian cycling when 
there is significant mood variation within a 24-hours period 
(Kramlinger and Post, 1996). Other terms include ultra-ultra 
rapid and ultradian rapid and refer to weekly or daily cycling, 
which is not uncommon in BD patients (Kramlinger and Post, 
1996). Most studies suggest a 5 to 33.3% up-to-1-year prevalence 
Table  2. Summary of the Frequencies of Appearance of Various 
Symptoms during the Two Different Acute Phases of BD
Episodes
Symptom Manic Depressive
Euphoria 30–97%
Expansive mood 44–66
Depressive symptoms 29–100% 100%
Mood lability 42–95%
Irritability 51–100% 75%
Psychomotor retardation 75%
Psychomotor acceleration 56–100%
Pressured speech 100%
Psychotic features 33–96%
Delusions 24–96% 12–66%
Hallucinations 13–66% 8–50%
Weight loss 25%
Weight gain 25%
Hyposomnia 63–100%
Oversleeping 25%
Loss of libido 25%
Hypersexuality 25–80%
Significant sexual exposure 23–33%
Confused 33%
Violent 46–75%
Regression, catatonia etc. 14–56%
Fecal incontinence 10–20%
Physical complains 66%
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(Kukopulos et  al., 1980; Nurnberger et  al., 1988; Coryell et  al., 
1992; Schneck et al., 2004, 2008; Azorin et al., 2008; Cruz et al., 
2008; Garcia-Amador et al., 2009; Lee et al., 2010) and 25.8 to 43% 
lifetime prevalence (Dittmann et  al., 2002; Coryell et  al., 2003; 
Yildiz and Sachs, 2004; Hajek et al., 2008; Lee et al., 2010).
In terms of neurocognitive function, the literature suggests 
that the neurocognitive deficit in BD patients concerns almost 
all domains and phases of the illness with only a few exceptions. 
Its magnitude is at the severe range during the acute episodes 
and at the medium range during euthymia, while the origin of 
the deficit remains unclear. In terms of neurocognitive function, 
BD patients do quantitatively better than patients with schizo-
phrenia, but the qualitative pattern of the deficit is similar in 
the 2 disorders. There are no clear differences between BD sub-
types. The deficit is present early in the course of the disorder. 
At least in some patients it might emerge before the onset of the 
first mood episode, and in the majority of patients it progresses 
probably in relationship with the manifestation of psychotic 
symptoms. The verbal memory and executive function deficit 
probably constitute endophenotypes, while the role of medica-
tion as a causative factor is limited (Tsitsipa and Fountoulakis, 
2015; Cullen et al., 2016).
Finally, in contrast to the original conceptualization of BD by 
Emil Kraepelin a century ago, unfortunately it seems that only 
a minority of BD patients achieve complete functional recovery 
(Goldberg et al., 1995a, 1995b; Keck et al., 1998; Strakowski et al., 
1998; Daban et al., 2006; Martinez-Aran et al., 2007; Mur et al., 
2007).
Classification
ICD and DSM include BD as a diagnostic entity but with signifi-
cant differences between them (Fountoulakis, 2015h). It is impor-
tant to note that almost all the research literature follows the 
DSM classification, while almost all countries worldwide have 
the obligation to use the ICD in their official documents, includ-
ing hospital records, etc. The ICD-10-CM helps to bridge these 
2 different classification systems for administration purposes. 
In ICD-10 (WHO, 1992, 1994), BD is included in the chapter on 
mood (affective) disorders (F30-F39). While in previous editions 
of the DSM, both unipolar and bipolar disorders were grouped 
under the chapter on mood disorders, on the contrary in DSM-5 
(American Psychiatric Association, 2013), BDs were separated 
from unipolar depression. The “bipolar” chapter includes BD and 
cyclothymic disorder, while the “depression” chapter includes 
disruptive mood dysregulation disorder, major depressive dis-
order, persistent depressive disorder (dysthymia), and premen-
strual dysphoric disorder. Both chapters include “unspecified,” 
“other,” and “due to” categories.
Another important difference between the 2 classification 
systems is that ICD requires the presence of at least 2 episodes 
of pathological disturbance of mood while DSM does not. DSM 
recognizes the presence of 2 subtypes of BD, that is, of BD-I (BD 
with manic episodes) and BD-II (BD with hypomanic but not 
manic episodes). BD-II is not part of the ICD-10 diagnostic list, 
which accepts hypomania as a diagnostic entity (F30.0), but it is 
considered simply a low-severity mania.
In ICD-10 a mixed affective episode (F38.0) is defined as an 
affective episode of at least 2 weeks duration that is character-
ized by either a mixture or a rapid alternation (usually within 
a few hours) of hypomanic, manic, and depressive symptoms. 
In DSM-5 a radical change was the abolishment of the concept 
of mixed episodes. In previous versions of the DSM, mixed epi-
sodes were defined as the coexistence of full-blown manic and 
depressive episodes simultaneously. Although such a coexist-
ence is rather rare, almost one-third of patients recruited in 
pharmaceutical trials of acute mania were diagnosed as mixed. 
Thus there exists ample data, although neither properly ana-
lyzed nor published. Instead of the diagnosis of mixed epi-
sodes, DSM-5 introduced the mixed features specifier concept. 
According to this, a mood episode (either manic or depressed) 
has mixed features if at least 3 criteria of the opposite pole 
(from a specific list) coexist. It is important to note that accord-
ing to DSM-5, mixed features can also be attributed to a unipolar 
major depressive episode without changing the diagnosis to BD.
Another important change in the DSM-5 is the introduction 
of the anxious distress specifier, which demands the presence of 
at least 2 criteria from a list of 5 (tension, restlessness, concen-
tration difficulties, worry, fear of losing control).
The ICD-10 classification accepts the presence of “somatic 
syndrome,” which sems analogous but it is not identical to “mel-
acholic features” of DSM-5 (Fountoulakis et al., 1999). The atypi-
cal features, rapid cycling, and anxious distress are described 
in DSM-5 but not in ICD-10. Also, ICD-10 does not differentiate 
psychotic symptoms into mood congruent vs mood incongru-
ent. The other specifiers, catatonia, peripartum onset, and sea-
sonal pattern, are not included in the ICD-10 either. It is also 
important to note that ICD-10 recognizes catatonia only in the 
frame of schizophrenia, while DSM-5 uses this specifier also in 
affective disorders.
There is an issue concerning the diagnosis of cases with sub-
threshold manic symptoms or long-lasting hyperthymia. While 
the traditional bipolar vs unipolar distinction is widely used and 
adopted by classification systems, it is doubtful whether it can 
capture the essence of the huge heterogeneity observed in mood 
disorders and their dynamic nature with frequent switches and 
changes in the clinical profile. The greatest disadvantage of both 
classification systems is that they perform better (and focus) 
when interepisodic remission is present; instead, the everyday 
real-life patient is more likely to suffer from a chronic disorder 
with residual and mixed symptoms. The term spectrum was 
first used in psychiatry in 1968 for the schizophrenia spectrum 
(Kety et al., 1968).
The proposed mood spectrum models unify categorical clas-
sification, which is essential, with a dimensional view, which is 
true to nature; both are needed and both are empirically test-
able. Today the term bipolar spectrum is mainly used in 2 com-
plementary senses: (1) a spectrum of severity, which embraces 
psychotic and nonpsychotic major and minor BDs (including 
bipolar dysthymia, recurrent brief and minor depressions), 
cyclothymic disorders, hypomania and, at its broadest, even 
borderline disorders and cyclothymic temperament; (2) a pro-
portional mood spectrum, which considers the 2 components, 
mania and depression, on the level of major and minor mood 
disorders. This proportional model is an extension of Kleist’s 
concept of BD as a combination of the 2 monopolar disorders of 
depression and mania (Kleist, 1937). Thus these 2 approaches to 
spectrum reflect 2 distinct continua: from normal to pathologi-
cal and from unipolar to bipolar.
An important part of the bipolar spectrum is cyclothymic 
disorder, which is considered to be an attenuated form of BD. 
Their behavior is characterized by the alternation of extremes 
(Akiskal et al., 1977). Depending on the threshold of traits used in 
determining the presence of hyperthymia, cyclothymic patients 
may constitute 10 to 20% of those with major depressive disor-
der. Also, cyclothymia is often a prodromal of BD (Akiskal et al., 
1979). Another important part of the bipolar spectrum are those 
patients who experience an antidepressant-induced switch. 
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Thus, many patients with so-called unipolar depression are 
actually pseudounipolar.
Some authors suggest that a significant part of the literature 
consists mostly of expert opinion overemphasizing various links 
between bipolar and unipolar mood disorders and personality 
disorders (Paris et al., 2007; Patten and Paris, 2008). Recently, the 
first solid international epidemiological data in support of the 
bipolar spectrum have been published (Merikangas et al., 2007, 
2011; Angst et al., 2010). According to these authors there is a 
direct association between increasingly restrictive definitions of 
BD and indicators of clinical severity, including symptom sever-
ity, role impairment, comorbidity, suicidality, and treatment. For 
example, the proportion of mood episodes rated as clinically 
severe increased from 42.5% for subthreshold BD to 68.8% for 
BD-II to 74.5% for BD-I. However, since clinical diagnosis and 
severity share confounding factors and definitions overlap, it 
is also important to note that these studies also showed that 
the proportion of cases reporting severe role impairment ranged 
from 46.3% for subthreshold BD to 57.1% for BD-I (Merikangas 
et al., 2011).
On the basis of both epidemiological data and clinical wis-
dom, a limited number of models reflecting the structure of 
the bipolar spectrum have been proposed. The first effort was 
a dimensional concept (from normal to pathological) proposed 
by Kretschmer in 1921 for schizophrenia (schizothymic-schiz-
oid-schizophrenic) and for affective disorders (cyclothymic 
temperament-cycloid ‘psychopathy’-manic-depressive disor-
der). Bleuler suggested a similar concept in 1922. In 1977 Akiskal 
proposed a cyclothymic-bipolar spectrum (Akiskal et al., 1977). 
A simple model system was introduced in 1978 by Jules Angst 
(1978; Angst et al., 1978), who used the the following codes: M for 
severe mania, D for severe depression (unipolar depression), m 
for less severe mania (hypomania), and d for less severe depres-
sion. In 1981 Gerald Klerman suggested a mania spectrum 
(Klerman, 1981, 1987) and in the late 1990s Akiskal proposed 6 
subtypes, some of which are further subdivided according to 
their unique clinical features. A summary of his proposed sub-
type schema is as follows (Akiskal and Pinto, 1999; Akiskal and 
Benazzi, 2005; Ng et al., 2007; Fountoulakis, 2008).
Epidemiology
In the last few decades there has been an increasing interest 
in psychiatric epidemiology. For BD, a point that plays a major 
role in the estimation of the prevalence rates is the definition of 
hypomania and of mixed, irritable, or dysphoric forms of manic 
episodes. This is further complicated by the presence of inaccu-
rate recall and the low sensitivity of the interview instruments 
concerning subthreshold symptomatology and nonclassical 
clinical pictures (Kessler et al., 1997a).
A number of important studies exist and provide impor-
tant but inconclusive information. The Amish study (Egeland 
and Hostetter, 1983; Egeland et al., 1983; Hostetter et al., 1983) 
reported similar prevalence rates between unipolar depression 
and bipolar illness and also similar rates between genders. It is 
impressive that 79% of patients with BD-I were previously diag-
nosed as suffering from schizophrenia. The Epidemiological 
Catchment Area study (ECA) (Eaton et  al., 1981; Regier et  al., 
1984, 1988, 1993; Bourdon et al., 1992) reported a lifetime preva-
lence of 0.8% for BD-I (0.3–1.2%) and an annual prevalence of 
0.6% (0.2–1%) with similar prevalence for males and females. 
The annual incidence was 0.4% (0.1–0.6%) of cases, which corre-
sponds to approximately 3.2 (0.8–4.8) per 100 000 residents. The 
median age at onset was 18 years. A reanalysis of the ECA data 
with the addition of subthreshold bipolarity produced a total 
lifetime prevalence of 6.4% with 0.5% being a lifetime preva-
lence of BD-II (Judd and Akiskal, 2003). The National Comorbidity 
Survey (NCS) (Kessler et  al., 1993, 1994a, 1994b, 1995, 1996, 
1997b; Blazer et  al., 1994; Wittchen et  al., 1994; Warner et  al., 
1995; Kendler et al., 1996; Magee et al., 1996) reported a lifetime 
prevalence of 1.7% for BD-I and an annual prevalence of 1.3% 
with similar prevalence for males and females. The median age 
at onset was 21  years. The NCS-R (Kessler et  al., 2004, 2005a, 
2005b, 2012a, 2012b; Kessler and Merikangas, 2004; Merikangas 
et al., 2007; Angst et al., 2010; Nierenberg et al., 2010) reported a 
lifetime prevalence of 1.0% for BD-I and an annual prevalence 
of 0.6% with again similar prevalence for males and females. 
The median age at onset was 19  years. For BD-II the lifetime 
prevalence was 1.1% and the annual prevalence was 0.8% with 
similar prevalence for males and females. The median age at 
onset was 20 years. There was a small difference between males 
and females in the BD-II rates, with female rates being slightly 
higher. The Cross National Collaboration Group study included 
data from 7 countries (US, Canada, Puerto Rico, Germany, 
Taiwan, South Korea and New Zealand) (Weissman et al., 1996) 
and reported variable rates for different countries, but overall 
the rates seemed moderately consistent cross-nationally. The 
Zurich study (Angst et al., 1984, 2005b; Wicki and Angst, 1991) 
reported an annual prevalence of BD-I of 0.7% and a lifetime 
prevalence for the bipolar spectrum of 5.5%. The Nottingham 
study (Brewin et  al., 1997) reported the 2-year incidence rate 
reported for BD was 0.005%, which corresponds to an annual 
incidence of 2.5/100 000. The Netherlands study (Bijl et al., 2002; 
Regeer et al., 2002; ten Have et al., 2002) suggested a lifetime 
prevalence of BD equal to 2.0%. The annual incidence was equal 
to 2.7/100 000. There was no significant difference between 
males and females. The Australian National Survey reported 
the year prevalence of euphoric BD (combined BD-I and BD-II) 
was 0.5% (Mitchell et al., 2004). The Butajira study from Ethiopia 
reported a lifetime prevalence of BD-I disorder of 0.5%, with the 
rate being 0.6% for males and 0.3% for females. The mean age 
of cases was 29.5 years, with no significant sex difference. The 
mean age of first recognition of illness was 22 years. There was 
no significant sex difference in the age at onset of manic or 
depressive phases (Negash et  al., 2005). A  more recent cross-
sectional, face-to-face, household survey in 11 countries in the 
Americas, Europe, and Asia reported that the lifetime preva-
lence was 0.6% for BD-I and 0.4% for BD-II, while the year preva-
lence was 0.4% and 0.3%, respectively (Merikangas et al., 2011). 
A few studies report on the epidemiology of bipolar spectrum 
and suggest that in the adult population the lifetime preva-
lence of the bipolar spectrum is between 3 and 8.3% (Weissman 
and Myers, 1978; Angst et al., 1984, 2005b; Oliver and Simmons, 
1985; Wicki and Angst, 1991; Heun and Maier, 1993; Angst, 1998; 
Szadoczky et al., 1998; Hirschfeld et al., 2003a, 2003b; Judd and 
Akiskal, 2003; Moreno and Andrade, 2005; Faravelli et al., 2006; 
Kessler et al., 2006).
Overall and according to the WHO, BD affected an estimated 
29.5 million persons worldwide in 2004 (WHO, 2008). The avail-
able data suggest that the life prevalence of BD-I is around 1%, 
with probably a similar rate concerning BD-II. The full bipolar 
spectrum probably has lifetime prevalence around 5%. There 
are no striking differences between genders. However these fig-
ures should be considered as only indicative, since important 
discrepancies exist among studies and countries, as mentioned 
above. The rather small difference between annual and lifetime 
rates suggests that BD is both an episodic but also a chronic 
mental disorder with high recurrence rates.
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The various studies from around the world suggest that the 
age at onset is late adolescence or early adulthood, around the age 
of 18 to 20 years, but also they suggest that approximately one-
fourth of BD patients have the onset before the age of 13 (Perlis 
et al., 2004; Post et al., 2008; Stringaris et al., 2010; Merikangas 
et al., 2012), and among other things this suggests caution in the 
use of stimulants for the treatment of children with ADHD and 
worse overall outcome (Agnew-Blais and Danese, 2016).
Staging
After the introduction of operationalized diagnostic criteria for 
all contemporary classification systems, the need to define and 
rate seriousness, progression, changes in physiology, and dam-
age made and the extent and the specific characteristics of the 
disease emerged. Staging is the term that defines this procedure 
(Fountoulakis, 2015k). The field in medicine where staging is most 
successful and enjoys great importance is that of clinical oncol-
ogy. Since 1993 there were many attempts to arrive at a staging 
model for psychiatry (Fava and Kellner, 1993; Yung and McGorry, 
1996, 2007; McGorry et al., 2006, 2007, 2010; McGorry, 2007, 2010b; 
Vieta et al., 2011; Cosci and Fava, 2013). The concept of staging 
if and when applied has a number of implications. Almost by 
definition it suggests that early stages are easier to treat, while 
later stages are rather refractory to treatment. Thus these later 
stages might need the application of treatment options with 
more adverse events, higher risk, and less overall benefit (Post 
et al., 2010) or some kind of palliative care should be considered.
The earliest research contribution to the effort of staging BD 
was the description of the stages of mania in the early 1970s when 
Carlson and Goodwin not only described discrete stages in the 
development and course of acute mania, but also they described 
a rollback phenomenon that is the clinical condition improves by 
manifesting the same stages but at a reverse order (Carlson and 
Goodwin, 1973). Up to n, 5 major staging models have been pro-
posed for BD (Berk et al., 2007a, 2007b; Kapczinski et al., 2009; Post, 
2010; Post et  al., 2012; Cosci and Fava, 2013; Frank et  al., 2014). 
Although there is some support for the proposed staging models, 
the research base is thin, the heterogeneity of the data is significant, 
and the studies include small sample sizes. A number of vicious 
logical cycles could be in place. Most of the data are cross-sectional 
(Kapczinski et al., 2014), and the need for a transdiagnostic and lon-
gitudinal research approach is prominent (Lin et al., 2013).
The data so far support the presence of an asymptomatic 
at-risk phase and a nonspecific prodromal phase. This prodro-
mal phase seems to be common for a number of mental disor-
ders, and prediction is extremely difficult on the basis of current 
knowledge. The literature is also supportive of the presence of 
an early stage of the full-blown illness, during which the epi-
sodes are well defined and there are no or very few inter-episode 
residual symptoms, good response to treatment, and little dis-
ability. It also supports the presence of a late stage that is associ-
ated with a more chronic and refractory disease, probably with 
depressive predominant polarity, psychotic features, and sig-
nificant disability. It is disappointing that there is little research 
on the treatment effect at late stages (Berk et  al., 2012), with 
only a few exceptions (Torrent et al., 2013). The use of biomark-
ers might, in the near future, facilitate the validation of staging 
systems and their therapeutic utility (Vieta, 2015).
Therapeutic Issues
The treatment of BD is complex (Fountoulakis, 2008) and for 
several decades the treatment of BD was theoretically based on 
the concept of mood stabilizers. This term was originally used 
during the 1950s to refer to a combination of amphetamine and 
a barbiturate to treat patients with neurotic instability but not 
patients with BD. The term mood normalizer was proposed by 
Mogens Schou for lithium (Schou, 1963), but eventually the sta-
bilizer concept prevailed, probably because the focus of research 
with lithium was on the long-term prophylaxis.
During the last decade, however, there was a plethora of data, 
mainly because of the introduction of atypical antipsychotics 
as possible treatment options. However, this gave the chance 
also for older substances to be tested under rigorously defined 
research conditions. These studies revealed that the treatment 
could be more complex than previously believed and several 
issues exist. The clinician should be aware of many specific 
indications, contraindications, details, and traps (Fountoulakis 
et al., 2005, 2007a, 2007b, 2008, 2015m; Gonda et al., 2009).
The concept of mood stabilizers is disputed, since the data 
do not support an equally wide efficacy for different compounds 
like lithium, valproate, or carbamazepine to warrant such a 
label. On the contrary, there are negative data concerning spe-
cific areas, while our knowledge is quite limited concerning 
other areas. One particular problem, which only recently has 
been awknowledged, is that probably some facets of the dis-
order are refractory to treatment. Another important problem 
is that not only is the evidence limited concerning the treat-
ment of specific facets and issues of BD (Fountoulakis, 2010; 
Fountoulakis et  al., 2012, 2013), but also continued scientific 
training and reading is inadequate. Thus, research findings are 
not making it to everyday clinical practice. Focused educational 
intervention might be nessessary to change this attitude. Part of 
this problem is reflected in the common practice among clini-
cians to use medication on the basis of a class effect. This means 
that they consider that a whole class of medications possesses a 
specific action. This class effect is often considered in combina-
tion with a syndromal approach, which means that irrespective 
of the nosological entity, a specific kind of symptoms respond to 
a specific class of medication.
For example, according to this combined approach all antip-
sychotics are equally effective against psychotic symptoms 
irrespective of disorder diagnosis, and the same holds for all 
antidepressants against depressive symptoms. This is the most 
commonly used approach in everyday clinical practice and has 
a huge impact on public mental health. Its significant advan-
tage is that it provides the clinician with fast and simple rules to 
determine treatment. On the other hand, its greatest problem is 
that this approach has been proven false, especially in the case 
of BD where it is specifically combined with a very broad mood 
stabilizers concept (Fountoulakis et  al., 2011). The extent to 
which this truly influences the everyday clinical practice world-
wide is unknown but is probably significant. The extent to which 
this concept influences the outcome of BD is similarly unknown, 
although theoretically a more evidence-based approach should 
improve the overall outcome of BD patients.
It is important to note that with the introduction of the 
second-generation antipsychotics, antipsychotics became a 
cornerstone for the treatment of BP also according to treatment 
guidelines. On the contrary, a number of studies showed that 
the usefulness of antidepressants that were traditionally seen 
in Europe as a meaningful treatment option for bipolar depres-
sion is questionable (Pacchiarotti et al., 2013b). Additionally, the 
maintenance/long-term treatment became more complex, since 
it has proven that agents previously considered to be mood sta-
bilizers were essentially more effective for one pole than the 
other (Popovic et al., 2012). This is definitely a fast-moving field, 
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and it is certainly difficult for a clinician to follow new findings 
and incorporate them into his or her everyday clinical practice.
On the other hand, the data on the usefulness of psychoso-
cial interventions are limited, and their value against specific 
symptoms and problems remains unknown (Fountoulakis et al., 
2009; Reinares et al., 2014).
One very special issue is agitation and its treatment. There 
is a significant number of published papers on the pharmaco-
logical (Citrome, 2004; Battaglia, 2005; Nordstrom and Allen, 
2007; Nordstrom et al., 2012) but also on the nonpharmacologi-
cal treatment of agitation (Marder, 2006; Amann et  al., 2013), 
while recently a consensus paper on how to treat agitation in 
BD patients has been published (Garriga et al., 2016).
Special Issues
Since BD is characterized by phases that respond to a com-
pletely different way to treatment, it is of outmost importance 
to define phases of treatment and comorbidity (Fountoulakis, 
2015f; Vrublevska and Fountoulakis, 2015).
It is relatively easy to define acute either manic/hypomanic or 
depressive episodes. However the terms continuation and mainte-
nance are often interchangeably used in the terminology of RCTs 
and thus create significant confusion (Frank et al., 1991; Ghaemi 
et al., 2004). Continuation treatment lasts up to 12 months, and 
the duration depends on an estimate of when the episode would 
have remitted spontaneously. On the other hand, maintenance 
treatment starts after remission and thus after continuation and 
covers several years. Although a strict definition demands at least 
2 months of sustained recovery for the patient to be considered 
in remission (American Psychiatric Association, 2000), the real-
ity is that only a minority of patients in RCTs achieve complete 
remission. This makes the use of terms (relapse vs recurrence 
and continuation vs maintenance) problematic. In the nomencla-
ture of RCTs, the terms relapse and maintenance are preferred. 
The FDA policy is to accept data, based on patients in remission 
for <2 months, thus adding to the continuation vs maintenance 
confusion of definitions (Calabrese et al., 2006).
The term relapse is also problematic in BD. A narrow defi-
nition suggests that relapses are of the same polarity with the 
index episode, and they tend to occur within the first months 
of improvement. However with a polymorphic disease like BD, 
it might be inappropriate not to include in relapses the early 
emergence of an episode of the opposite pole. It is important to 
note that licensing authorities accept the latter approach.
The acute episode after which BD patients are enrolled into 
maintenance trials is called the index episode. To date, most 
maintenance trials follow an enriched design, that is, only 
patients who have remitted under the investigation agent dur-
ing the acute phase are enrolled into the double blind mainte-
nance phase. This design has interesting consequences, since it 
biases the sample both towards a specific predominant polar-
ity and also towards a favorable response to the specific agent 
(Cipriani et al., 2014). These 2 comments constitute important 
limitations in the generalizability of the results and make very 
difficult the translation of research findings into the everyday 
clinical practice in the case of patients who, rather than contin-
ued on the same medication, are switched to another one dur-
ing the maintenance phase (Grande et al., 2014).
Economic Considerations
It is very difficult to calculate the true economic cost of a poly-
morphic disorder like BD. The cost includes direct spending due 
to hospitalizations and medication, cost of supporting infrastruc-
ture of the various National Health Systems, somatic comorbid-
ity, indirect and out-of-pocket costs, as well as the absenteeism 
from work and premature death (Fountoulakis, 2015g).
For the UK the total cost has been estimated to be £2.055 billion 
in 1999/2000 prices (Das Gupta and Guest, 2002). It is interesting 
that 86% of this cost was the result of productivity loss and unem-
ployment, while only 10% was cost related with NHS services. 
Medication costs in primary care were approximately £8.5 million, 
corresponding to 0.4% of total cost and 4.3% of NHS cost. A more 
recent study showed that the NHS cost has been doubled, with 
medication costs rising disproportionally and reaching £25.2 mil-
lion, that is 7.4% of NHS cost (Young et al., 2011). In the US, the cost 
of medication was rather very low during the 1990s and reached 
2% of the total cost after 2000, but the exact figure is unknown 
(Wyatt and Henter, 1995; Begley et al., 2001; McCrone et al., 2008; 
Dilsaver, 2011). In Germany the total annual cost was calculated 
to be 5.8 million euros, with 98% being due to productivity loss 
(Runge and Grunze, 2004). Similar estimations come from other 
areas of the world, with the calculations basing on different preva-
lence rates and health systems and societal structures (Hakkaart-
van Roijen et al., 2004; Fisher et al., 2007; Ekman et al., 2013).
It is clear that the cost of medication treatment constitutes 
a very small percentage of the total cost of BD (Hidalgo-Mazzei 
et  al., 2015). Medication treatment is, however, the interven-
tion with the greatest impact on the course of the illness and 
the intervention that makes possible other actions to exist 
by resolving acute episodes in a reliable way. Furthermore, it 
decreases the long-term impairment and improves insight and 
collaboration by the side of the patient. Nevertheless, it also 
seems clear that medication cost is disproportionally rising, at 
least in some places of the world and for periods of time, and 
this constitutes an additional factor of concern. One should be 
very careful, because a small reduction in medication costs as a 
consequence of giving priority to cheaper agents and disregard-
ing clinical data could easily result in a significant and dispro-
portional increase in the total cost of the disease.
The CINP workgroup decided not to take medication cost 
or availability of medication into consideration. It chose to rely 
exclusively on clinical data, leaving the cost and availability 
issues to local and national groups who would like to imple-
ment the CINP guidelines in a specific country or region and 
would be obliged to take into consideration also the local socio-
political and economic environment.
Methodology
The workgroup decided after consensus to follow the following 
methodology for the development of the treatment algorithm 
with the steps listed below:
a) Defining the sources of data and choosing which to use
b) Development of a grading method
c) Search of the literature
d) Grading of the data
e) Defining the clinical parameters to take into consideration
f) Development of a precise treatment algorithm
g) Development of the clinical guideline
Defining the Sources of Data and Choosing Whom 
to Use
Randomized Controlled Trials (RCTs)
This type of study constitutes the main source of evidence. 
Without them it is impossible to say whether an agent or 
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method possesses efficacy or not, since it is impossible to con-
trol for confounding variables any other way. Randomization of 
patients to parallel treatment arms, including placebo, allows 
one to attribute confidently observed differences in efficacy 
between these arms to the effects of the treatments (McAlister 
et al., 1999a, 1999b; Pocock and Elbourne, 2000).
However, with BD there is an important problem. Because 
of ethical, practical, and most often economic limitations, it is 
not always possible to apply the RCT method across all facets 
and issues of BD. For many of them, data are available only on 
the basis of posthoc analyses or secondary outcomes. Another 
major limitation is that this kind of study is very expensive, and 
thus most of them are industry sponsored with the objective to 
obtaining the label for the specific product. Although such trials 
follow the regulatory agencies’ design, they have limitations on 
generalizability. Also it is well known that only a small minor-
ity of highly selected patients is eligible to enter these studies, 
and thus the generalizability of results is problematic. The study 
duration is often relatively short and this is true also for main-
tenance trials, in part because the existence of a placebo arm 
carries a high attrition rate.
An important pitfall concerns the actual results of the RCT, 
which often are different from those published. It is not unu-
sual that when a trial is negative on the basis of its primary 
outcome, a publication is done on the basis of positive second-
ary outcomes. This is essentially misleading, but fortunately it 
is a phenomenon that has been less frequent during the recent 
years.
Meta-Analysis
Meta-analysis is a technique that combines data (not simply 
pooled) from several trials and returns a specific quantitative 
answer to a specific question that usually is which treatment is 
superior in comparison with others or placebo. Sometimes but 
not always it also provides an absolute estimate of the treat-
ment effect size.
There are a number of significant limitations for the meta-
analytic methods (Huf et al., 2011a, 2011b). There is a need for 
the studies included in the meta-analysis to be similar in design 
and with sufficient information being available. Meta-analytic 
studies often violate this rule and include a diverse group of 
trials in the analysis (e.g., studies of monotherapy and combi-
nation treatment, fixed and flexible dosage studies, etc.) with 
unknown consequences (Fountoulakis et al., 2014).
Common problems of meta-analyses include small sample 
sizes, inadequate power, study heterogeneity, lack of extract-
able data, lack of interchangeable measurement instruments 
and definitions of outcomes, and other differences in the design 
of studies whose data are utilized. Negative trials are often not 
published and this poses an important limitation to the meta-
analytic approach. Today the trials sponsored by official founda-
tions can be traced in trial repositories. However, their detailed 
results are unlikely to be retrieved and even if they are retrieved, 
they have not undergone the essential peer review process 
(which adds credibility) like those published, and their quality 
could be questionable.
The question whether it is appropriate to use data from the 
largest possible number of disparate studies vs the need for 
including data only from essentially identical studies is a matter 
of debate and has also been discussed specifically concerning 
acute mania trials where these different approaches gave con-
flicting results (Yildiz et al., 2010; Cipriani et al., 2011). Practically, 
all meta-analytical studies utilize compromises to deal with the 
above problems and limitations. These compromises might 
have profound effects on the validity and generalizability of 
their results (Noble, 2006; Mismetti et al., 2007; Huf et al., 2011b).
Some authors consider meta-analysis to be on the top of the 
evidence-based pyramid of data sources. This approach suggests 
that its results are superior to the results of the RCTs, and sub-
sequently it is meant that a positive meta-analysis is superior 
to a number of negative RCTs even in the case of the absence 
of any positive RCTs. However, the authors of the current paper 
consider that in most cases meta-analysis has a lower evidence 
level than RCTs and therefore graded it below them, primarily 
because of a significant number of limitations and drawbacks 
that often make the results of meta-analysis equivocal.
Open Trials
Open trials do not utilize the double blind design and they are 
not placebo controlled. Therefore they are easier to conduct, 
their number and size are greater, and the quality of patients 
enrolled is closer to that seen in the real world. Their great limi-
tation is that their open nature induces significant bias, and 
thus they are by no means considered to be even close to being 
the gold standard or a reliable source of evidence data. Their 
role should be considered complementary. It is not unusual that 
treatment modalities with many positive open trials fail in RCTs, 
with topiramate in BD being a striking example (Suppes, 2002).
Review and Opinion Papers
Review and opinion papers mainly constitute educational tools, 
which attempt to translate the research findings into ready-to-
use tools for the everyday clinical practice. They are extremely 
useful for the average clinician; however, they usually echo the 
opinion of the author, and thus they might contain significant 
bias. Their overall reliability and validity is questionable and 
only a few add significantly to our understanding by critically 
analyzing the existing data. Their ever-increasing number in the 
literature might constitute a problem, since they often obscure 
research findings by reproducing widely established biases and 
misconceptions. This is an important problem especially in the 
field of BD treatment.
Sources to Include
The authors decided by consensus to include only RCTs and 
meta-analyses in the development of the current treatment 
algorithm, since they have the highest validity for judgment. 
The authors reserved the privilege to judge and use the second 
and third source on an individual basis and according to their 
research and clinical experience for the latter steps of the algo-
rithm where a Delphi method to arrive at decisions was utilized.
Development of a Grading Method
The authors decided to develop a grading method for the evalu-
ation of available data concerning the treatment of BD. Such 
methods have existed since the early 1980s (Fletcher and Spitzer, 
1980), but the de novo development of such a method was 
judged to be absolutely necessary, because the existing grading 
methods were not sufficiently appropriate for use in this par-
ticular set of data. In the frame of this process, the most widely 
accepted grading methods were studied, and their advantages 
and disadvantages were identified and taken into considera-
tion in relationship to the specific needs of the current study. All 
grading methods include a method to assess the quality of data 
and a method to arrive at recommendations on the basis of the 
extent to which we can be confident that the desirable effects 
of an intervention outweigh the undesirable effects. The values 
 by guest on N
ovem
ber 18, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
10 | International Journal of Neuropsychopharmacology, 2016
and preferences factor as well, but the cost was not taken into 
consideration by the workgroup.
Starting in 1992, 5 steps were developed to summarize the 
process of individual-level decision making and they were pub-
lished in 2005 (Dawes et al., 2005). They include:
a.  The formulation of a precise and answerable question and 
avoiding uncertainty and vague statements (Richardson 
et al., 1995; Schlosser et al., 2007).
b.  The performance of a systematic search and retrieval of 
the evidence available (Rosenberg et al., 1998).
c.   The critical review and classification of the retrieved evi-
dence with the recognition of the presence of systematic 
errors, various types of bias, confounders, reliability and 
validity issues, etc. The clinical significance and the gener-
alizability of the results should also be taken into account 
(Parkes et al., 2001; Horsley et al., 2011).
d.  Application of results in practice.
e.  Evaluation of performance (Jamtvedt et  al., 2003, 2006a, 
2006b; Ivers et al., 2012).
It is important to assess the quality of the evidence that comes 
from the sources described above. The quality assessment is 
based on the strength of their freedom from the various biases 
that beset medical research. In this frame, triple-blind, placebo-
controlled trials with allocation concealment and complete 
follow-up involving a homogeneous patient population and 
medical condition should be considered to constitute the high-
est grade, while case reports should be considered to constitute 
the lowest grade. Expert opinion should not be considered to be 
a source of evidence, although it could be a valuable tool for the 
development of guidelines (Tonelli, 1999).
Until recently there were a number of grading systems for 
assessing the quality of evidence that were developed by differ-
ent organizations. One of them is the U.S. Preventive Services Task 
Force (U.S. Preventive Services Task Force, 1989; Sherman et  al., 
2011) and another system is the Oxford (UK) Center for Evidence 
Based Medicine Levels of Evidence, which also is useful for the grad-
ing of diagnostic tests, prognostic markers, or harm (Oxford (UK) 
Center for Evidence Based Medicine Levels of Evidence Working 
Group) and constituted the basis for the use of the BCLC staging 
system for diagnosing and monitoring hepatocellular carcinoma 
in Canada (Paul et al., 2012). Another method to grade data is the 
Patient Outcomes Research Team (PORT) method (Lehman and 
Steinwachs, 1998), which has been used by the World Federation of 
Societies of Biological Psychiatry for the development of the WFSBP 
guidelines (Grunze et al., 2002, 2003, 2004). In 1992 the Agency for 
Health Care Policy and Research and the National Institute of Mental 
Health established a PORT for Schizophrenia at the University of 
Maryland School of Medicine and the Johns Hopkins University 
School of Public Health. The PORT investigators adopted the criteria 
on levels of evidence used for development of the Agency for Health 
Care Policy and Research Depression Guidelines.
The most detailed and precise modern method seems to 
be the GRADE method (short for Grading of Recommendations 
Assessment, Development and Evaluation) for the develop-
ment of guidelines (Guyatt et al., 2008b; Jaeschke et al., 2008), 
which clearly separates quality of evidence from level of rec-
ommendation and suggests it is necessary to include a clear 
question that should include all 4 components of clinical man-
agement (patients, an intervention, a comparison, and the out-
comes of interest) (Oxman and Guyatt, 1988) and to grade the 
outcomes into those who are critical for the decision making 
and those who are not (Schunemann et al., 2006). In this frame, 
the assessment of the quality of evidence is important, since it 
reflects the confidence whether the effect is adequate to sup-
port recommendations. The determinants of quality are study 
limitations, inconsistency of results, indirectness of evidence, 
imprecision, and reporting bias (Guyatt et  al., 2011a, 2011b, 
2011c, 2011d, 2011e, 2013). There is some option to upgrade the 
quality when the effect size is very high (Guyatt et al., 2011f). 
The GRADE method provides guidance to grade the data from 
a variety of sources (Guyatt et al., 2008a), but it is not sensitive 
for datasets that focus solely on RCTs like the dataset of the 
current workgroup. According to the GRADE grading system, all 
the data included in the current effort to develop guidelines are 
of high quality. From the limitations recognized by the GRADE 
(lack of allocation concealment, lack of blinding, large losses to 
follow-up, failure to adhere to an intention to treat analysis, and 
stopping early for benefit or failure to report outcomes), only 
large losses to follow-up and stopping early for benefit or fail-
ure to report outcomes could be applicable to the current study. 
A comparison of all the grading methods is shown in Table 3.
Table 3. Comparative Presentation of Different Grading Methods
USPSTF OCEBM GRADE PORT
Systematic review of randomized 
trials or n-of-1 trials
High quality Level A: Good research-based 
evidence, with some expert 
opinion, to support the 
recommendation
Level I: Evidence obtained from at least one 
properly designed randomized controlled trial.
Randomized trial or observational 
study with dramatic effect
Level II-1: Evidence obtained from well-designed 
controlled trials without randomization.
Medium quality Level B: Fair research-based 
evidence, with substantial 
expert opinion, to support the 
recommendation
Nonrandomized controlled cohort/
follow-up study
Low quality
Level II-2: Evidence obtained from well-designed 
cohort or case-control analytic studies, 
preferably from more than one center or 
research group.
Case-series, case-control studies, 
or historically controlled studies
Very low quality
Level II-3: Evidence obtained from multiple time 
series designs with or without the intervention. 
Dramatic results in uncontrolled trials might 
also be regarded as this type of evidence.
Mechanism-based reasoning Level C: Recommendation based 
primarily on expert opinion, with 
minimal research-based evidence, 
but significant clinical experience
Level III: Opinions of respected authorities, based 
on clinical experience, descriptive studies, or 
reports of expert committees.
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The recommendation methods constitute a step forward and 
are determined by the balance of risk vs benefit of the inter-
vention and the level of evidence on which this information is 
based. A  comparison of the recommendation methods of the 
U.S. Preventive Services Task Force uses (Sherman et al., 2011) 
that utilizes a 5-levels system and the GRADE system that has 
only 2 categories concerning recommendations and charac-
terizes them as strong (conditional) and weak (discretionary) 
(Guyatt et  al., 2008b, 2008c) and also considers cost (Brunetti 
et al., 2013) is shown in Table 4.
As defined previously, only RCTs were taken into consideration, 
a fact that puts all the data at the highest grading according to all 
systems. However, the workgroup was concerned about a number 
of issues, including inconsistency of results between RCTs, con-
flicting results between RCTs and meta-analyses, issues explored 
only on the basis of secondary outcomes, etc. After recognizing all 
these sources of problematic quality, 32 individual scenarios were 
identified and are listed in Table 5. Afterwards they were ranked 
after consensus and grouped into levels. Two solutions were pro-
posed. The ranking, the 4- and 5-levels solution, and the final grad-
ing system are shown in Table 6. The description of the grading 
and the recommendation systems are shown in Table 7.
At this point it is important to note that the absence of evi-
dence is not identical with the presence of negative data.
Table 4. Comparative Presentation of Recommendation Methods
USPSTF GRADE
Level A: Good scientific evidence suggests that the benefits of the clinical service substantially outweigh the potential risks. Strong
Level B: At least fair scientific evidence suggests that the benefits of the clinical service outweighs the potential risks.
Level C: At least fair scientific evidence suggests that there are benefits provided by the clinical service, but the balance between 
benefits and risks are too close for making general recommendations.
Weak
Level D: At least fair scientific evidence suggests that the risks of the clinical service outweighs potential benefits.
Level I: Scientific evidence is lacking, of poor quality, or conflicting, such that the risk versus benefit balance cannot be assessed.
Abbreviations: GRADE, Grading of Recommendations Assessment, Development and Evaluation for the Development of Guidelines; OCEBM, Oxford (UK) Center for 
Evidence Based Medicine; PORT, Patient Outcomes Research Team; USPSTF, U.S. Preventive Services Task Force.
Table 5. The 32 Different Scenarios That Were Identified, Listed, and Graded
Primary Outcome Scenarios
 1. At least 1 positive 2-active arm RCTs vs placebo exist, plus positive 1 active arm RCTs. No negative RCTs
 2. At least 2 positive RCTs vs placebo exist. No negative RCTs
 3. One positive RCT vs placebo exists. No negative RCTs
 4. Some positive plus some negative RCTs vs placebo. Positive all meta-analyses
 5. Some positive plus some negative RCTs vs placebo. Mixed results from meta-analyses
 6. Some positive plus some negative RCTs vs placebo. Negative all meta-analyses
 7. More positive but some negative RCTs vs placebo. Positive all meta-analyses
 8. More positive but some negative RCTs vs placebo. Mixed results from meta-analyses
 9. More positive but some negative RCTs vs placebo. Negative all meta-analyses
10. More negative but some positive RCTs vs placebo. Positive all meta-analyses
11. More negative but some positive RCTs vs placebo. Mixed results from meta-analyses
12. More negative but some positive RCTs vs placebo. Negative all meta-analyses
13. Only 1 negative trial exists vs placebo
14. Only negative trials exist vs placebo. Meta analyses all negative
15. Only negative trials exist vs placebo. Meta analyses all positive
16. Only negative trials exist vs placebo. Meta analyses mixed
Posthoc scenarios
17. Only 1 positive from posthoc analyses vs placebo
18. At least 2 positive from posthoc analyses vs placebo
19. Only 1 negative from posthoc analyses vs placebo
20. At least 2 negative from posthoc analyses vs placebo. Positive all meta-analyses
21. At least 2 negative from posthoc analyses vs placebo. Negative all meta-analyses
22. At least 2 negative from posthoc analyses vs placebo. mixed meta-analyses
23. More negative than positive from posthoc analyses vs placebo. Positive all meta-analyses
24. More negative than positive from posthoc analyses vs placebo. Negative all meta-analyses
25. More negative than positive from posthoc analyses vs placebo. mixed meta-analyses
26. More positive than negative from posthoc analyses vs placebo. Positive all meta-analyses
27. More positive than negative from posthoc analyses vs placebo. Negative all meta-analyses
28. More positive than negative from posthoc analyses vs placebo. mixed meta-analyses
Other scenarios
29. Only 1 failed trial, no other data
30. At least 2 failed trials, no other data
31. Only prematurely terminated trials
32. Although trials exist, the data are not available in a way to arrive at reliable conclusions
Abbreviations: GRADE, Grading of Recommendations Assessment, Development and Evaluation) for the Development of Guidelines; USPSTF, U.S. Preventive Services 
Task Force.
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All treatment agents were graded also in terms of safety and tol-
erability. All combination options were graded at best with 2, since 
they put the patient at a higher risk for manifesting adverse events.
Search of the Literature
The workgroup decided that the PRISMA method (Hopewell 
et al., 2008; Liberati et al., 2009; Moher et al., 2009a, 2009b) should 
be followed in the search of the literature, which will include 3 
kinds of papers:
i.   RCTs (placebo controlled as well as clinical trials with an 
active comparator with the compounds used as mono-
therapy or add-on therapy).
ii.   Posthoc analyses of RCTs
iii.  Meta-analyses and review papers
iv.   Treatment guidelines papers
The search strategies will include:
1. To locate RCTs, the combination of the words ‘bipolar,’ 
‘manic,’ ‘mania,’ ‘manic depression,’ and ‘manic depressive’ 
and ‘randomized’ will be used.
2. Webpages containing lists of clinical trials will be scanned. 
These sites include http://clinicaltrials.gov and http://www.
clinicalstudyresults.org as well as the official sites of all 
the pharmaceutical companies with products used for the 
treatment of BD.
3. Relevant review articles will be scanned and their reference 
lists will be utilized.
4. The MEDLINE will be searched with the combination of 
keywords ‘guidelines’ or ‘algorithms’ with ‘mania,’ ‘manic,’ 
‘bipolar,’ ‘manic-depressive,’ or ‘manic depression.’
5. The treatment guidelines will also be scanned and their 
reference lists will be utilized.
6. Only papers in English language will be included.
Additionally, an unstructured search of the literature will be per-
formed concerning the adverse events and other safety issues of 
treatment options
The workgroup considered the fact that it is difficult to locate 
unpublished studies, especially old ones, and even more diffi-
cult to retrieve their results. Thus it was decided that the focus 
should be put mainly on published studies which are definitely 
peer reviewed, are of higher quality, and provide more details 
than meeting abstracts or report sheets. However, whenever an 
unpublished trial should be located, it is mentioned in the spe-
cific part of the manuscript. The authors decided not to seek 
for additional information concerning unpublished trials from 
manufacturers, because this might increase the retrieval bias.
Grading of the Data
The grading of the data will follow their retrieval and will be 
done according to the method developed and described in the 
Table 6. The Ranking, the 4- and 5-levels Solution, and the Final Grading System for the 32 Different Scenarios
Solutions
Scenario Rank 5-Grade 4-Grade Grade system
At least 1 positive 2-active arm RCTs vs placebo exist, plus positive 1 active arm RCTs. No 
negative RCTs
1 A A 1
At least 2 positive RCTs vs, placebo exist. No negative RCTs 1 A A 1
One positive RCT vs placebo exists. No negative RCTs 2 A B 2
More positive but some negative RCTs vs placebo. Positive all meta-analyses 2 A B 2
Some positive plus some negative RCTs vs placebo. Positive all meta-analyses 3 B B 2
More negative but some positive RCTs vs placebo. Positive all meta-analyses 4 B B 2
Only negative trials exist vs placebo. Meta analyses all positive 4 B B 2
At least 2 positive from posthoc analyses vs placebo 5 B C 3
Only 1 positive from posthoc analyses vs placebo. 5 B C 3
Some positive plus some negative RCTs vs placebo. Mixed results from meta-analyses 6 C C 3
More positive but some negative RCTs vs placebo. Mixed results from meta-analyses 6 C C 3
More positive than negative from posthoc analyses vs placebo. Positive all meta-analyses 7 D C 3
More negative than positive from posthoc analyses vs placebo. Positive all meta-analyses 7 D C 3
At least 2 negative from posthoc analyses vs placebo. Positive all meta-analyses 7 D C 3
More positive than negative from posthoc analyses vs placebo. mixed meta-analyses 8 E C 3
More negative but some positive RCTs vs placebo. Mixed results from meta-analyses 9 E D 4
Only negative trials exist vs placebo. Meta analyses mixed 9 E D 4
At least 2 negative from posthoc analyses vs placebo. Mixed meta-analyses 10 E D 4
More negative than positive from posthoc analyses vs placebo. Mixed meta-analyses 10 E D 4
Some positive plus some negative RCTs vs placebo. Negative all meta-analyses neg neg neg 5
More positive but some negative RCTs vs placebo. Negative all meta-analyses neg neg neg 5
More negative but some positive RCTs vs placebo. Negative all meta-analyses neg neg neg 5
Only 1 negative trial exists vs placebo neg neg neg 5
Only negative trials exist vs placebo. Meta analyses all negative neg neg neg 5
Only 1 negative from posthoc analyses vs placebo neg neg neg 5
At least 2 negative from posthoc analyses vs placebo. Negative all meta-analyses neg neg neg 5
More negative than positive from posthoc analyses vs placebo. Negative all meta-analyses neg neg neg 5
More positive than negative from posthoc analyses vs placebo. Negative all meta-analyses neg neg neg 5
Only prematurely terminated trials neg neg neg 5
Although trials exist, the data are not available in a way to arrive at reliable conclusions neg neg neg 5
Only 1 failed trial, no other data unknown unknown unknown
At least 2 failed trials, no other data unknown unknown unknown
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current paper. The grading will be included in the second paper 
concerning the CINP guidelines for BD
Defining the Clinical Parameters to Take into 
Consideration
In the real-world setting, the therapist encounters patients with 
specific clinical features that often determine the choice of treat-
ment on the basis of clinical experience and wisdom rather than 
evidence. These features include the so-called core manic and core 
depressive features, psychotic features, anxiety, the co-occurrence 
of manic and depressive symptoms in a variety of combinations 
that often do not correspond to concepts accepted by modern clas-
sification systems, agitation, and rapid cycling. It is interesting to 
address the complete constellation of symptoms instead of a spe-
cific group. The problem is that the data often focus on the second 
rather than the first option. It is important also to consider the pre-
dominant polarity and subtype of BD (BD-I vs BD-II), the personal 
history of the patient, and more specifically previous response or 
refractoriness to treatment and adverse events (including switch).
The data will be scanned concerning the treatment of all the 
above conditions and modifiers and relevant conclusions will be 
made concerning whether they can be used as clinical cues for 
the selection of appropriate treatment.
Development of a Precise Algorithm
The development of a precise algorithm for experimental rea-
sons will be the first task. This algorithm will be based exclusively 
on the evidence and will be the next step after the data and the 
interventions are graded in terms of recommendation. This algo-
rithm will be based on the data in a narrow and strict sense and 
might provide with very precise but limited treatment options 
for the everyday clinical practice. There will be no trade between 
the evidence-based approach and clinical utility; the first will be 
absolutely dominant. This algorithm will reflect the exact state 
of the art concerning hard data but will lack any clinical wisdom, 
and it is expected that its application in everyday clinical practice 
will be problematic. Therefore it should be considered as experi-
mental, and clinicians who will wish to apply it in their clinical 
practice should do so by taking into consideration these advan-
tages and disadvantages. The algorithm will be included in the 
second paper concerning the CINP guidelines for BD, and it will be 
accompanied by a detailed table with the grading recommenda-
tion of all available interventions during all the phases of BD and 
in relevance with the presence of specific clinical features.
At a later time point a software application will be developed 
by the CINP to assist with the use of the algorithm.
Development of the Clinical Guideline
The development of the guideline will follow after the data and 
the interventions have been graded and the presice algorithm 
has been developed. The guideline will be included in the third 
paper concerning the CINP guidelines for BD. The workgroup 
decided after consensus on the following rules for the develop-
ment of the guidelines:
i.  Overall the guideline should be based on existing research 
hard evidence, but also it should make sense for the 
everyday clinical practice and should be user friendly. 
Although their nature will be based on the evidence-based 
approach, this should not go too far concerning the inter-
pretation of the research findings and the potential clinical 
implications.
Table 7. Summary of the Method for the Grading of the Data and Recommendation as Decided by the Workgroup on the Basis of Both Efficacy 
and Safety Tolerability
Grading on Basis of Efficacy
Level 1 Good research-based evidence, supported by at least 2 placebo controlled studies of sufficient magnitude and good quality. 
In case of the presence of negative RCTs, positive RCTs should outnumber negative ones
Level 2 Fair research-based evidence, from one randomised, double-blind placebo controlled trial.
Also in case one or more trials exist, however, they fail to fulfil all the criteria above (e.g., very small sample size or no 
placebo control) as well as in case of positive meta-analysis alone.
Level 3 Some evidence from comparative studies without placebo arm or from posthoc analyses.
Level 4 Inconclusive data or poor quality of RCTs
Level 5 Negative data
Grading on the basis of safety and tolerability
Level 1 Very good tolerability, few side effects which are not enduring, they do not cause significant distress and are not life- 
threatening and they do not compromise the overall somatic health of the patient
Level 2 Moderate tolerability, many side effects which could be enduring, and cause significant distress but they are not life- 
threatening although they could compromise the overall somatic health of the patient.
Agents with very good overall tolerability but with rare life-threatening adverse events, could be classified here only if 
the lethality risk can be essentially considered to be negligible with the application of procedures and protocols (e.g., 
laboratory testing, titration schedules, etc.)
Level 3 Poor tolerability, many side effects which are enduring, cause significant distress, compromise the overall somatic health 
of the patient or are life-threatening.
Agents with moderate overall tolerability and rare life-threatening adverse events should be classified here even in cases 
the lethality risk can be essentially considered to be negligible with the application of procedures and protocols (e.g., 
laboratory testing, titration schedules, etc.)
Recommendations for treatment (combination of efficacy and safety/tolerability)
Level 1 Level 1 or 2 for efficacy and 1 for safety/tolerability
Level 2 Level 1 or 2 for efficacy and 2 for safety/tolerability
Level 3 Level 3 for efficacy and 1 or 2 for safety/tolerability
Level 4 Level 4 for efficacy or 3 for safety/tolerability
Level 5 Level 5 for efficacy (not recommended)
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ii.  Agents and treatment modalities with proven efficacy 
across all 3 phases of the illness (acute mania, acute 
bipolar depression, and maintenance phase concerning 
the prevention of both manic and depressive episodes) 
should be given priority.
iii.  No economic and availability issues will be taken into 
consideration. National bodies that might wish to utilize 
the CINP guidelines could add such analyses tailored to 
the specific country or region.
Discussion
The current paper sets the frame for the development of the 
CINP treatment guidelines for BD. It contains all the background 
information, including important clinical features, staging 
methods, and important treatment issues and details. It also 
elaborates on the methodology to be used and describes the 
development of a grading system that will be suitable for use 
with the kind of data under consideration.
The overall aim of the workgroup was to push guidelines one 
step further by evaluating the available data in depth and also 
by identifying clinical issues that need specific interventions 
that could be supported by the data. A significant contribution 
is expected to be the precise experimental algorithm that will 
constitute an option for further study.
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